Home > Rheumatology > ACR 2021 > Psoriatic Arthritis: Novel Developments > Selective IL-23 inhibition: a new option in active PsA

Selective IL-23 inhibition: a new option in active PsA

Presented By
Prof. Andrew Östör, Monash University, Australia

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
ACR 2021
Trial
Phase 3, KEEPsAKE 1, KEEPsAKE 2
Results of the KEEPsAKE 1 and 2 trials demonstrated high efficacy of the IL-23 blocker risankizumab in adult patients with active psoriatic arthritis (PsA), independent of previous therapy. Risankizumab also showed an excellent safety profile. The selective IL-23 inhibitor risankizumab has already been approved for moderate-to-severe psoriasis and is being investigated as a treatment for adults with PsA. At the ACR meeting, 2 presentations covered the phase 3 KEEPsAKE trials, which compared risankizumab with placebo [1,2]. In a plenary session, Prof. Andrew Östör (Monash University, Australia) presented an integrated analysis of data from the KEEPsAKE 1 (NCT03675308) and KEEPsAKE 2 (NCT03671148) studies, including 1,407 patients with active PsA who had inadequate res...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on